Phase 3
N=34
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
Gaucher Disease, Type 1
Bottom Line
View on ClinicalTrials.gov: NCT00553631 ↗Enrolled (actual)
34
Serious AEs
8.8%
Results posted
Jan 2011
Primary outcome: Primary: Mean Change From Baseline to Month 9 in Hemoglobin (Hgb) Concentration for Each Treatment Group. — 1.624; 1.488 gram per deciliter (g/dl)
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- velaglucerase alfa (Biological); imiglucerase (Biological)
- Age
- Pediatric, Adult, Older Adult · 2+ yrs
- Sex
- All
- Sponsor
- Shire
- Primary completion
- May 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Change From Baseline to Month 9 in Hemoglobin (Hgb) Concentration for Each Treatment Group. |
1.624; 1.488 | — |
| SECONDARY Change From Baseline to Month 9 in Platelet Counts for Each Treatment Group. |
110.41; 144.38 | — |
| SECONDARY Change From Baseline to Month 9 in Normalized Liver Volume (Percent (%) Body Weight) for Each Treatment Group. |
-1.31; -1.10 | — |
| SECONDARY Change From Baseline to Month 9 in Normalized Spleen Volume (Percent (%) Body Weight) for Each Treatment Group. |
-1.34; -2.46 | — |
| SECONDARY Change From Baseline to Month 9 in Plasma Chitotriosidase for Each Treatment Group. |
-34711.9; -35109.5 | — |
| SECONDARY Change From Baseline to Month 9 in Plasma Chemokine (C-C Motif) Ligand 18 (CCL18) for Each Treatment Group. |
-926.2; -1153.4 | — |
| SECONDARY Number of Participants Who Developed Antibody for Each Treatment Group. |
0; 4 | — |
| SECONDARY Time to Response- Comparison of GA-GCB and Imiglucerase on the Earliest Time to Respond as Assessed Via Hemoglobin Concentration |
92.9; 100 | — |
Summary
Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this non-inferiority study is to evaluate the efficacy and safety of GA-GCB (velaglucerase alfa) administered every other week in comparison to imiglucerase in treatment naive patients with type 1 Gaucher disease.
Eligibility Criteria
Inclusion Criteria
Includes:
- The patient has a documented diagnosis and clinical manifestation of type 1 Gaucher disease
- The patient is at least 2 years of age.
- The patient has not received treatment for Gaucher disease (investigational products, miglustat, or imiglucerase) within 12 months prior to study entry, as documented in the patient's medical history.
- Female patients of child-bearing potential must agree to use a medically acceptable method of contraception at all times during the study and must have negative results to a pregnancy test performed at the time of enrollment and as required throughout their participation in the study. Male patients must use a medically acceptable method of birth control throughout their participation in the study and must report their partner's pregnancy.
- The patient, the patient's parent(s) or legal guardian(s) has provided written informed consent that has been approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC).
- The patient must be sufficiently cooperative to participate in this clinical study as judged by the Investigator.
Exclusion Criteria
Includes:
- The patient has type 2 or 3 Gaucher disease or is suspected of having type 3 Gaucher disease.
- The patient has received treatment with any non-Gaucher disease-related investigational drug or device within the 30 days prior to study entry; such use during the study is not permitted.
- The patient is known to be positive for human immunodeficiency virus (HIV).
- The patient is known to be positive for hepatitis B and/or C.
- The patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study.
- The patient has a significant comorbidity(ies) that might affect study data or confound the study results (e.g., malignancies, primary biliary cirrhosis, autoimmune liver disease, etc.).
- The patient is unable to comply with the protocol, e.g., has a clinically relevant medical condition making implementation of the protocol difficult, has an uncooperative attitude, is unable to return for safety evaluations, or is otherwise unlikely to complete the study, as determined by the Investigator.
Data sourced from ClinicalTrials.gov (NCT00553631). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.